Navigating FDA clinical trials in Neurotech with Tim Marjenin

Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & the startups building it

Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & the startups building it! 🍄

Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.

Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges.

In this episode, we discuss:

• Different regulatory pathways for neurological devices (510(k), De Novo, PMA)

• FDA's approach to novel neurotechnologies like brain-computer interfaces (BCIs)

• Considerations for invasive vs. non-invasive neurotech devices

• The importance of cybersecurity in neurotechnology

• Common mistakes companies make in the regulatory process and how to avoid them

• The potential future of neurotechnology, including human augmentation and telepathy

Listen to the episode here, on Spotify, or on Apple Podcasts.

Once you've finished the episode, we'd love to hear your thoughts! Tweet us at @psymedventures or email us at hi@psymed.ventures to share your views.

P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏